NZ798451A - Variant staphylococcus aureus luka and lukb polypeptides and vaccine compositions - Google Patents
Variant staphylococcus aureus luka and lukb polypeptides and vaccine compositionsInfo
- Publication number
- NZ798451A NZ798451A NZ798451A NZ79845121A NZ798451A NZ 798451 A NZ798451 A NZ 798451A NZ 798451 A NZ798451 A NZ 798451A NZ 79845121 A NZ79845121 A NZ 79845121A NZ 798451 A NZ798451 A NZ 798451A
- Authority
- NZ
- New Zealand
- Prior art keywords
- luka
- staphylococcus aureus
- variant
- lukb
- vaccine compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063084273P | 2020-09-28 | 2020-09-28 | |
| PCT/US2021/052418 WO2022067255A2 (en) | 2020-09-28 | 2021-09-28 | Variant staphylococcus aureus luka and lukb polypeptides and vaccine compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ798451A true NZ798451A (en) | 2024-11-29 |
Family
ID=80846955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ798451A NZ798451A (en) | 2020-09-28 | 2021-09-28 | Variant staphylococcus aureus luka and lukb polypeptides and vaccine compositions |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240050546A1 (https=) |
| EP (1) | EP4216982A4 (https=) |
| JP (1) | JP2023544300A (https=) |
| KR (1) | KR20230091911A (https=) |
| CN (1) | CN116670158A (https=) |
| AR (1) | AR123635A1 (https=) |
| AU (1) | AU2021350860A1 (https=) |
| CA (1) | CA3195895A1 (https=) |
| CL (1) | CL2023000884A1 (https=) |
| CO (1) | CO2023004198A2 (https=) |
| IL (1) | IL301406A (https=) |
| JO (1) | JOP20230065A1 (https=) |
| MX (1) | MX2023003581A (https=) |
| NZ (1) | NZ798451A (https=) |
| WO (1) | WO2022067255A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3215751A1 (en) * | 2021-04-02 | 2022-10-06 | Janssen Pharmaceuticals, Inc. | Staphylococcus aureus vaccine compositions |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1340522C (en) * | 1987-03-10 | 1999-05-04 | Heinz Dobeli | Fusion proteins containing neighbouring histidines for improved purification |
| SE0102327D0 (sv) * | 2001-06-28 | 2001-06-28 | Active Biotech Ab | A novel engineered superantigen for human therapy |
| EP4015523A1 (en) * | 2010-05-05 | 2022-06-22 | New York University | Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof |
| RU2016110800A (ru) * | 2013-09-25 | 2017-10-30 | Пронутриа Биосайенсис, Инк. | Составы и композиции для поддержания и увеличения мышечной массы, силы и результативности, и способы их производства и использования |
| EP3464349A4 (en) * | 2016-05-23 | 2020-08-26 | New York University | COMPOSITIONS AND METHODS ASSOCIATED WITH ANTIBODIES TARGETING STAPHYLOCCAL LEUCOTOXINS |
| EP3638286A4 (en) * | 2017-06-13 | 2021-03-10 | Integrated Biotherapeutic Vaccines, Inc. | IMMUNOGENIC COMPOSITIONS CONTAINING POLYPEPTIDES DERIVED FROM LEUCOCIDINS LUKA AND LUKB OF STAPHYLOCOCCUS AUREUS |
| CA3215751A1 (en) * | 2021-04-02 | 2022-10-06 | Janssen Pharmaceuticals, Inc. | Staphylococcus aureus vaccine compositions |
-
2021
- 2021-09-28 WO PCT/US2021/052418 patent/WO2022067255A2/en not_active Ceased
- 2021-09-28 CA CA3195895A patent/CA3195895A1/en active Pending
- 2021-09-28 US US18/028,477 patent/US20240050546A1/en active Pending
- 2021-09-28 CN CN202180065630.5A patent/CN116670158A/zh active Pending
- 2021-09-28 EP EP21873641.1A patent/EP4216982A4/en active Pending
- 2021-09-28 JP JP2023519355A patent/JP2023544300A/ja active Pending
- 2021-09-28 KR KR1020237014304A patent/KR20230091911A/ko active Pending
- 2021-09-28 AR ARP210102696A patent/AR123635A1/es unknown
- 2021-09-28 IL IL301406A patent/IL301406A/en unknown
- 2021-09-28 AU AU2021350860A patent/AU2021350860A1/en active Pending
- 2021-09-28 MX MX2023003581A patent/MX2023003581A/es unknown
- 2021-09-28 NZ NZ798451A patent/NZ798451A/en unknown
-
2023
- 2023-03-27 CL CL2023000884A patent/CL2023000884A1/es unknown
- 2023-03-28 JO JOJO/P/2023/0065A patent/JOP20230065A1/ar unknown
- 2023-03-30 CO CONC2023/0004198A patent/CO2023004198A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240050546A1 (en) | 2024-02-15 |
| CL2023000884A1 (es) | 2023-09-29 |
| IL301406A (en) | 2023-05-01 |
| JP2023544300A (ja) | 2023-10-23 |
| AR123635A1 (es) | 2022-12-28 |
| EP4216982A4 (en) | 2025-03-19 |
| WO2022067255A2 (en) | 2022-03-31 |
| CN116670158A (zh) | 2023-08-29 |
| JOP20230065A1 (ar) | 2023-03-28 |
| CA3195895A1 (en) | 2022-03-31 |
| AU2021350860A1 (en) | 2023-05-04 |
| EP4216982A2 (en) | 2023-08-02 |
| KR20230091911A (ko) | 2023-06-23 |
| CO2023004198A2 (es) | 2023-07-31 |
| MX2023003581A (es) | 2023-06-21 |
| WO2022067255A3 (en) | 2022-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA522433360B1 (ar) | L-أَسْباراجيناز مُعدل | |
| EP4272765A3 (en) | Adeno-associated virus (aav) clade f vector and uses therefor | |
| HRP20231496T1 (hr) | Cistein proteaza | |
| IL173253A0 (en) | Polypeptides for inducing a protective immune response against staphylococcus aureus | |
| JP2018531040A5 (https=) | ||
| EP4442816A3 (en) | Mutated glycoprotein of vesicular stomatitis virus | |
| NZ603016A (en) | Novel immunotherapy against several tumors including neuronal and brain tumors | |
| NZ627111A (en) | Variants of activin iib receptor polypeptides and uses thereof | |
| NZ596787A (en) | Growth hormone polypeptides and methods of making and using same | |
| JP2024041747A5 (https=) | ||
| NZ798451A (en) | Variant staphylococcus aureus luka and lukb polypeptides and vaccine compositions | |
| EA201792362A8 (ru) | Композиции и способы для лечения целиакии спру | |
| JP2015504052A5 (https=) | ||
| NZ736652A (en) | Short synthetic peptide for treating diseases and/or conditions related to angiogenesis | |
| CO2024016693A2 (es) | Péptido con actividad antimicrobiana | |
| MX2023001219A (es) | Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus. | |
| MX394834B (es) | Proteína de fusión para usarse en el tratamiento/prevención de una infección por virus de hepatitis b. | |
| WO2006033918A3 (en) | Polypeptides for inducing a protective immune response against staphylococcus aureus | |
| NZ768123A (en) | Variants of porcine trypsin | |
| PH12022550667A1 (en) | Staphylococcus peptides and methods of use | |
| MY171183A (en) | Polypeptide glycosylated with sialylated sugar chain | |
| WO2022031733A3 (en) | Keratinolytic polypeptides and methods of use | |
| WO2017140913A3 (en) | Fusion proteins | |
| MX2023007406A (es) | Composiciones que comprenden ciclotidos y otros peptidos insecticidas y usos de las mismas. | |
| JP2023544300A5 (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 SEP 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20250815 |